NCT03553108View on ClinicalTrials.gov

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

March 12, 2019

Study Completion Date

July 1, 2020

Conditions
Malignant Solid Tumor
Interventions
DRUG

Olaparib Treatment A

Olaparib Tablet 25 mg

DRUG

Olaparib Treatment B

Olaparib Tablet 100 mg

DRUG

Olaparib Treatment C

Olaparib Tablet 150 mg

DRUG

Olaparib Treatment D

Olaparib Tablet 250 mg

Trial Locations (3)

2610

Research Site, Wilrijk

3000

Research Site, Leuven

4000

Research Site, Liège

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AstraZeneca

INDUSTRY